Showing 8391-8400 of 8821 results for "".
- KYTHERA Biopharmaceuticals, Inc. Names F. Michael Ball to Boardhttps://practicaldermatology.com/news/20130925-kythera_biopharmaceuticals_inc_names_f_michael_ball_to_board/2459451/KYTHERA Biopharmaceuticals, Inc. has named F. Michael (Mike) Ball, Chief Executive Officer (CEO) of Hospira, Inc. to its Board of Directors. Mr. Ball brings more than 25 years of healthcare experience to KYTHERA. Mr. Ball was appointe
- GSK Receives FDA Priority Review for Dabrafenib/Trametinib Combination in Metastatic Melanomahttps://practicaldermatology.com/news/20130916-gsk_receives_priority_review_from_fda_for_dabrafenibtrametinib_combination_in_metastatic_melanoma/2459460/The FDA has granted priority review designation to GlaxoSmithKline's supplemental New Drug Applications (sNDAs) for combined use of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or
- Caliber Imaging & Diagnostics Introduces VivaScope 1500 Multilaser Systemhttps://practicaldermatology.com/news/20130910-caliber_imaging__diagnostics_introduces_vivascope_1500_multilaser_system/2459465/Caliber Imaging & Diagnostics, formerly Lucid, Inc., recently introduced the VivaScope 1500 Multilaser system, cellular imaging devices that give researchers the option of a painless, no
- Anacor Submits NDA, Presents Data for Tavaborolehttps://practicaldermatology.com/news/20130830-anacor_submits_nda_presents_data_for_tavaborole/2459469/Anacor Pharmaceuticals has submitted an NDA to the FDA for for Tavaborole, its drug candidate for the topical treatment of onychomycosis. The company recently reported data presented at this summer's 2013 APMA Annual Scientific Meeting. Findings s
- FDA Approves Mirvaso for Treating Facial Erythema of Rosaceahttps://practicaldermatology.com/news/20130826-fda_approves_mirvaso_for_treating_facial_erythema_of_rosacea/2459476/The FDA recently approved Mirvaso (brimonidine) gel, 0.33% for the topical treatment of the facial erythema of rosacea in adults 18 years of age or older. According to manufacturer Galderma Laboratories, applied once
- Merz North America Appoints New Chief Financial Officerhttps://practicaldermatology.com/news/20130807-merz_north_america_appoints_new_chief_financial_officer/2459482/Merz North America has appointed John Donofrio as Chief Financial Officer and Head of Business Development - North America. In this role, Donofrio will be primarily accountable for financial performance, cost management, and strategic business planning and analysis for the Finance organization in No
- Positive Findings Published for Provectus Pharmaceuticals' PV-10https://practicaldermatology.com/news/20130726-positive_findings_published_for_provectus_pharmaceuticals_pv-10/2459491/Positive research conducted at the Moffitt Cancer Center with intralesional PV-10 has been published in PLOS ONE, an international, peer-reviewed, open-access, online publication,
- Congress Establishes New Caucus on Skin Cancerhttps://practicaldermatology.com/news/20130708-congress_establishes_new_caucus_on_skin_cancer/2459502/A new bipartisan Congressional Member Organization will address the growing epidemic of skin cancer among Americans. Led by representatives Jim Cooper (D-TN-5th), Carolyn Maloney (D-NY-12th), Peter Roskam (R-IL-6th), and Charlie Dent (R-PA-15th), the caucus will support legislative activities and pr
- Merz North America Appoints New Vice Presidenthttps://practicaldermatology.com/news/20130702-merz_north_america_appoints_new_vice_president/2459503/Greg Besase has been appointed Vice President of Merz North America. Besase joined Merz in December 2012 as Director of Marketing, Dermatology and has served as the interim head of the U.S. Dermatology Business Unit since February 2013.
- Allergan Appoints Douglas S. Ingram as Presidenthttps://practicaldermatology.com/news/20130702-allergan_appoints_douglas_s_ingram_as_president/2459504/Douglas S. Ingram was appointed as President of Allergan. In this role, Mr. Ingram will lead the company's global commercial operations, with responsibility for the company's broad portfolio of pharmaceutical, consumer, and medical device product